

AMENDMENT TRANSMITTAL LETTER

Docket No.
02420/1001249-US2

Application No.
10/076,905-Conf. #1884

Filing Date
February 14, 2002

Examiner
S. L. Rawlings

Art Unit
1643

Applicant(s): Ze'ev Ronai

Invention: INHIBITION OF ATF2 ACTIVITY TO TREAT CANCER

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	45	- 44 =	1	x	
Independent Claims	5	- 5 =		x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify): Request for continued examination (RCE) (see 37 CFR 1.114)					420.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					420.00


- ☐ Large Entity ☒ Small Entity
- ☐ No additional fee is required for this amendment.
- ☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$ 420.00 to cover the filing fee is enclosed.
- ☐ Payment by credit card. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 04-0100
as described below. A duplicate copy of this sheet is enclosed.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

Mitchell Bernstein
Mitchell Bernstein, Reg. No. 46,550 for

Dated: December 9, 2005

Stephanie R. Amoroso, Ph.D.
Attorney Reg. No.: 51,401

DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7770



Express Mail Label No.

Dated: _____

Docket No.: 02420/100I249-US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ze'ev Ronai

Application No.: 10/076,905

Confirmation No.: 1884

Filed: February 14, 2002

Art Unit: 1643

For: INHIBITION OF ATF2 ACTIVITY TO
TREAT CANCER

Examiner: S. L. Rawlings

AMENDMENT AND REQUEST FOR CONTINUED EXAMINATION

(37 C.F.R. SECTION 1.114)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action mailed September 9, 2005, please amend the above-identified U.S. patent application as follows. Exhibit 1, database sequences of the human wild-type ATF2 protein, accompanies this Amendment and is referenced in the Remarks section of this Response.

Accompanying this Amendment is a Request for Continued Examination and the requisite fee. Should the U.S. Patent and Trademark Office determine that additional fees are owed or that any refund is owed for this application, the Commissioner is hereby authorized and requested to charge the required fee(s) and/or credit the refund(s) owed to our Deposit Account No. 04-0100.

{W:\02420\100I249US2\00584993.DOC {XX}}

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 15 of this paper.

Remarks/Arguments begin on page 21 of this paper.